Correlation Between Immix Biopharma and Royalty Pharma

Can any of the company-specific risk be diversified away by investing in both Immix Biopharma and Royalty Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immix Biopharma and Royalty Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immix Biopharma and Royalty Pharma Plc, you can compare the effects of market volatilities on Immix Biopharma and Royalty Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immix Biopharma with a short position of Royalty Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immix Biopharma and Royalty Pharma.

Diversification Opportunities for Immix Biopharma and Royalty Pharma

-0.69

Correlation Coefficient

Immix Biopharma  Royalty Pharma

Excellent diversification

The 3 months correlation between Immix and Royalty is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Immix Biopharma and Royalty Pharma Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Pharma Plc and Immix Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immix Biopharma are associated (or correlated) with Royalty Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Pharma Plc has no effect on the direction of Immix Biopharma i.e., Immix Biopharma and Royalty Pharma go up and down completely randomly.

Pair Corralation between Immix Biopharma and Royalty Pharma

Given the investment horizon of 90 days Immix Biopharma is expected to generate 6.63 times more return on investment than Royalty Pharma. However, Immix Biopharma is 6.63 times more volatile than Royalty Pharma Plc. It trades about 0.2 of its potential returns per unit of risk. Royalty Pharma Plc is currently generating about -0.15 per unit of risk. If you would invest  165.00  in Immix Biopharma on September 27, 2024 and sell it today you would earn a total of  53.00  from holding Immix Biopharma or generate 32.12% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Immix Biopharma  vs.  Royalty Pharma Plc

Immix Biopharma

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Immix Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak primary indicators, Immix Biopharma showed solid returns over the last few months and may actually be approaching a breakup point.

Royalty Pharma Plc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Royalty Pharma Plc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with Immix Biopharma and Royalty Pharma

The main advantage of trading using opposite Immix Biopharma and Royalty Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immix Biopharma position performs unexpectedly, Royalty Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will offset losses from the drop in Royalty Pharma's long position.

The idea behind Immix Biopharma and Royalty Pharma Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.